The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction.

[1]  J. Heit.  Perioperative Management of the Chronically Anticoagulated Patient , 2001, Journal of Thrombosis and Thrombolysis.

[2]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[3]  C. Francis,et al.  Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients : A double-blind, randomized comparison , 2000 .

[4]  T. Peters,et al.  A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. , 2000, The Journal of urology.

[5]  T. Peters,et al.  A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. , 2000, The Journal of urology.

[6]  P. Leprince,et al.  Low molecular weight heparin after mechanical heart valve replacement. , 2000, Circulation.

[7]  R. Hahn,et al.  Clinical outcome 1 year after transurethral vaporization and resection of the prostate. , 2000, Urology.

[8]  G. Raskob,et al.  Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism , 2000 .

[9]  D. Cranston,et al.  A double‐blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3‐year follow‐up , 2000, BJU international.

[10]  W. Shingleton,et al.  A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia. , 1999, Urology.

[11]  J. Roberts,et al.  Immediate and postoperative complications of transurethral prostatectomy in the 1990s. , 1999, The Journal of urology.

[12]  H. Weitz,et al.  Use of enoxaparin for the chronically anticoagulated patient before and after procedures. , 1999, The American journal of cardiology.

[13]  S. Carrera,et al.  Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. , 1999, Journal of vascular surgery.

[14]  P. Lindmarker.  Can All Patients with Deep Vein Thrombosis Receive Low-Molecular-Weight Heparin in an Outpatient Setting? , 1999, Pathophysiology of Haemostasis and Thrombosis.

[15]  Pasi,et al.  Thrombotic risk factors associated with transurethral prostatectomy , 1999, BJU international.

[16]  M. Ezekowitz,et al.  Preventing stroke in patients with atrial fibrillation. , 1999, JAMA.

[17]  Chakravarti,et al.  Transurethral resection of the prostate in the , 1998 .

[18]  J. Weitz.  Low-molecular-weight heparins. , 1997, The New England journal of medicine.

[19]  J. Daurès,et al.  Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta‐analyses , 1997, The British journal of surgery.

[20]  J. Hirsh,et al.  Management of anticoagulation before and after elective surgery. , 1997, The New England journal of medicine.

[21]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[22]  R. Verhaeghe,et al.  A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. , 1995, American journal of surgery.

[23]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[24]  N. Parr,et al.  Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. , 1989, British journal of urology.

[25]  B. Gersh,et al.  The natural history of lone atrial fibrillation. A population-based study over three decades. , 1987, The New England journal of medicine.

[26]  G. Rose,et al.  RISK OF STROKE IN NON-RHEUMATIC ATRIAL FIBRILLATION , 1987, The Lancet.

[27]  Fisher Cm.  Reducing risks of cerebral embolism. , 1979 .

[28]  P. Wolf,et al.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke , 1978, Neurology.

[29]  L. F. Greene,et al.  Transurethral prostatic resection in patients with prosthetic cardiac valves. , 1975, The Journal of urology.

[30]  J. Hirsh,et al.  Managing oral anticoagulant therapy. , 2001, Chest.

[31]  M. Kovacs,et al.  Outpatient Treatment of Pulmonary Embolism with Dalteparin , 2000, Thrombosis and Haemostasis.

[32]  A. Berstad,et al.  Bleeding effects of unfractionated heparin and low molecular weight heparins in an animal model. , 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.